GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioAtla Inc (NAS:BCAB) » Definitions » Price-to-Owner-Earnings

BCAB (BioAtla) Price-to-Owner-Earnings : (As of Dec. 14, 2024)


View and export this data going back to 2020. Start your Free Trial

What is BioAtla Price-to-Owner-Earnings?

As of today (2024-12-14), BioAtla's share price is $1.45. BioAtla does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for BioAtla's Price-to-Owner-Earnings or its related term are showing as below:


BCAB's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 31.405
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-12-14), BioAtla's share price is $1.45. BioAtla's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.70. Therefore, BioAtla's PE Ratio (TTM) for today is At Loss.

As of today (2024-12-14), BioAtla's share price is $1.45. BioAtla's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.70. Therefore, BioAtla's PE Ratio without NRI for today is At Loss.


BioAtla Price-to-Owner-Earnings Historical Data

The historical data trend for BioAtla's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioAtla Price-to-Owner-Earnings Chart

BioAtla Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

BioAtla Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioAtla's Price-to-Owner-Earnings

For the Biotechnology subindustry, BioAtla's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioAtla's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioAtla's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where BioAtla's Price-to-Owner-Earnings falls into.



BioAtla Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

BioAtla's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.45/-1.97
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioAtla  (NAS:BCAB) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


BioAtla Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of BioAtla's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


BioAtla Business Description

Traded in Other Exchanges
N/A
Address
11085 Torreyana Road, San Diego, CA, USA, 92121
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Executives
Sylvia Mcbrinn director
Short Jay M Phd director, 10 percent owner, officer: Chief Executive Officer C/O DIVERSA CORPORATION, 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Christian Vasquez officer: See Remarks 121 E. PALOMAR STREET, CHULA VISTA CA 91911
Lawrence Steinman director 10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Eddie Williams director 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Scott Andrew Smith director, officer: President C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Eric Sievers officer: Chief Medical Officer 11085 TORREYANA ROAD, SAN DIEGO CA 92121
Richard A Waldron officer: Chief Financial Officer 901 MARINERS ISLAND BLVD STE.205, SAN MATEO CA 94404
Guy Levy director, 10 percent owner C/O SOLEUS PRIVATE EQUITY GP I, LLC, 104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Soleus Pe Gp I, Llc 10 percent owner 104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Himalaya Parent Llc 10 percent owner 11085 TORREYANA ROAD, SAN DIEGO CA 92121
Susan Moran director 1232 RICHARDSON AVE, LOS ALTOS CA 94024
Carolyn Anderson Short 10 percent owner, officer: See Remarks 11085 TORREYANA ROAD, SAN DIEGO CA 92121
Priyanka Belawat director C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142